Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2009 - 2026)

Vertex Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$431.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 674.01% year-over-year to -$431.9 million in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 21.78% increase from a year earlier, with the FY2025 full-year figure at -$945.4 million, up 74.92% from the prior year.
• Cash from Investing Activities declined to -$431.9 million in Q1 2026 per VRTX's latest filing, from -$288.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $175.6 million in Q4 2022 and bottomed at -$2.1 billion in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$348.0 million (2024), against an average of -$506.5 million.
• Across the five-year window, Cash from Investing Activities soared 231.04% in 2022 and plunged 3495.29% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $175.6 million in 2022, then slumped by 604.84% to -$886.5 million in 2023, then climbed by 7.29% to -$821.9 million in 2024, then jumped by 64.95% to -$288.1 million in 2025, then tumbled by 49.91% to -$431.9 million in 2026.
• Per Business Quant, the three latest VRTX Cash from Investing Activities figures stand at -$431.9 million (Q1 2026), -$288.1 million (Q4 2025), and -$117.0 million (Q3 2025).